Change in management at Dr. Falk Pharma
12.04.2023 17:26
Effective April 1, 2023, Dr. Kai Pinkernell is the management of the Science & Innovation division at Dr. Falk Pharma GmbH in Freiburg-Hochdorf was taken over. In this role he succeeds Dr. Roland Greinwald, who retired at the end of March 2023 after 30 years. Together with Philipp Argast, Managing Director Finance & Administration, and Torben Zachmann, Managing Director Commercial, Dr. Kai Pinkernell will take over the management of Dr. Falk Pharma GmbH.
“I am particularly pleased about the opportunity to work in your internationally successful company. Together with all of you, I would like to advance the projects that have been initiated and demonstrate the innovative strength of Dr. “Falk Pharma will continue to expand,” said Dr. Kai Pinkernell told the staff when he joined the company. Dr. Kai Pinkernell, who has been working in drug research at home and abroad for many years, has many years of experience in the field of clinical research and innovative therapeutic approaches.
The specialist in digestive and metabolic medicine had already repositioned itself at the beginning of the year. With a clear focus on innovative products in the field of gastroenterology and hepatology, the development areas (Science & Innovation) will be strengthened in the future. “We are very pleased to have Dr. We were able to win Kai Pinkernell for us. His international expertise in preclinical and clinical research will provide a lot of inspiration and will make a significant contribution to expanding our product portfolio. We have a lot planned, particularly in the area of chronic inflammatory bowel disease, celiac disease, gastroparesis and liver diseases. Due to our internationally growing business, we would also like to further expand and strengthen the area of in- and out-licensing as well as partnering activities. We are therefore particularly pleased to have Dr. “Having Kai Pinkernell on board for this,” says Dr. Martin Falk, partner of Dr. Falk Pharma GmbH.
Dr. Roland Greinwald has managed the family company's product innovations since 2000. On April 1, 1993, he joined clinical research as a project manager, seven years later took over responsibility for research and development and joined the management in 2018. “Dr. Roland Greinwald has motivated colleagues all over the world and made a crucial contribution to the success of our company in his roles within research and development. We are sincerely and beyond grateful to him for his excellent work and his tireless commitment to the company. We wish him the very best for his new phase of life, combined with health, and say from the bottom of our hearts: THANK YOU,” said Carola Falk, partner of Dr. Falk Pharma GmbH, farewell to Dr. Roland Greinwald.